1. Home
  2. LASE vs TCRX Comparison

LASE vs TCRX Comparison

Compare LASE & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Laser Photonics Corporation

LASE

Laser Photonics Corporation

N/A

Current Price

$1.29

Market Cap

55.3M

Sector

Industrials

ML Signal

N/A

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

N/A

Current Price

$0.78

Market Cap

49.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LASE
TCRX
Founded
2019
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
55.3M
49.4M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
LASE
TCRX
Price
$1.29
$0.78
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.00
AVG Volume (30 Days)
1.8M
470.5K
Earning Date
04-20-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.28
EPS
N/A
N/A
Revenue
$721,185.00
$10,325,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$19.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
266.65
52 Week Low
$0.38
$0.72
52 Week High
$6.77
$2.57

Technical Indicators

Market Signals
Indicator
LASE
TCRX
Relative Strength Index (RSI) 50.71 44.78
Support Level $0.83 $0.73
Resistance Level $1.30 $0.80
Average True Range (ATR) 0.10 0.04
MACD 0.03 0.01
Stochastic Oscillator 55.78 50.25

Price Performance

Historical Comparison
LASE
TCRX

About LASE Laser Photonics Corporation

Laser Photonics Corp is an integrated manufacturing company for photonics-based industrial products and solutions, laser cleaning technologies. Its laser-blasting technologies are focused on disrupting the sandblasting and abrasive blasting markets. The company offers a portfolio of integrated laser-blasting solutions for corrosion control, rust removal, de-coating, pre-welding and post-welding, laser cleaning, and surface conditioning. Its laser-blasting solutions are applicable in every industry dealing with materials processing, including automotive, aerospace, healthcare, consumer products, shipbuilding, machine manufacturing, nuclear maintenance and decommissioning, and surface coating. Geographically, the company generates almost all of its revenue from the domestic market.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: